However, when she went to nursery the staff noticed that her speech was not developing properly. Doctors initially believed ...

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 26 years, gives his ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The company has made significant advancements in its discussions with the FDA regarding the Rett syndrome study, focusing on functional gains and restoration of milestones as key endpoints. This ...

BMO Capital analyst Keith Tapper CFA has maintained their bullish stance on TSHA stock, giving a Buy rating today. Keith Tapper CFA’s ...

for the treatment of Rett syndrome in adult and paediatric patients two years of age and older. Neuren's NNZ-2591 drug is in ...

Greetings, and welcome to the Taysha Gene Therapies' third-quarter 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...